Immatics NV (IMTX)
11.02
-0.26
(-2.30%)
USD |
NASDAQ |
May 31, 16:00
11.02
0.00 (0.00%)
After-Hours: 20:00
Immatics Cash from Financing (Quarterly): 189.70M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 189.70M |
| December 31, 2023 | -1.580M |
| September 30, 2023 | 54.28M |
| June 30, 2023 | 39.73M |
| March 31, 2023 | -0.9301M |
| December 31, 2022 | 112.11M |
| September 30, 2022 | 2.162M |
| June 30, 2022 | 16.97M |
| March 31, 2022 | -0.7731M |
| Date | Value |
|---|---|
| December 31, 2021 | -0.7017M |
| September 30, 2021 | -0.7654M |
| June 30, 2021 | -1.044M |
| March 31, 2021 | -0.5808M |
| December 31, 2020 | -5.519M |
| September 30, 2020 | 244.21M |
| June 30, 2020 | -0.6121M |
| March 31, 2020 | -0.6743M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.519M
Minimum
Dec 2020
244.21M
Maximum
Sep 2020
38.00M
Average
-0.6121M
Median
Jun 2020
Cash from Financing (Quarterly) Benchmarks
| MorphoSys AG | -- |
| Affimed NV | -1.482M |
| InflaRx NV | -0.0931M |
| BioNTech SE | -8.472M |
| CureVac NV | -1.221M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -35.42M |
| Cash from Investing (Quarterly) | -262.66M |
| Free Cash Flow | -29.05M |
| Free Cash Flow Per Share (Quarterly) | -0.4284 |
| Free Cash Flow to Equity (Quarterly) | -45.38M |
| Free Cash Flow to Firm (Quarterly) | -45.38M |
| Free Cash Flow Yield | -3.00% |